GRAIL Clears a Major FDA Hurdle for Its Cancer Blood Test — But Can the Stock Keep Climbing Without Insurance Coverage?

Shares of GRAIL surged to $150.24, extending a breathtaking +38% rally since September 22, after an FDA advisory panel gave a decisive thumbs-up to the company's blood-based cancer screening test. The panel voted 7-2 that the test's benefits outweigh its risks, unanimously endorsed its safety, and split 6-4 on its effectiveness. The question now is whether the stock — already trading at the upper end of analyst targets — has room to run before the FDA's final ruling and the harder battle for insurance reimbursement.

A Strong Vote, but the FDA Still Has the Final Say. The panel's recommendation is non-binding — the FDA makes the final approval decision — but an advisory green light is generally seen as a strong signal of how the agency will rule.

The FDA is expected to make a final decision in the coming months , with management expecting approval in early 2027. That gap between now and the ruling means the stock will likely trade on sentiment and speculation, not certainty.

The Real Revenue Gate Is Insurers, Not the FDA. GRAIL's test is already sold on an out-of-pocket basis. Sales will really grow when medical insurers start covering it, and while FDA approval isn't strictly necessary for insurers to cover it, in practice, it is a prerequisite for widespread coverage.

President Trump signed a law authorizing Medicare to cover FDA-approved multi-cancer detection tests, but that coverage won't start until 2028. Until then, revenue depends on patients willing to pay themselves and the handful of early employer-health-plan deals GRAIL has struck.

The Numbers Reveal a Company Still Burning Cash. Total revenue in Q2 grew 26% year-over-year to $44.7 million.

Investors were concerned about the $110 million net loss and $82 million cash burn that quarter. GRAIL remains unprofitable, with trailing earnings per share of -$9.75 and negative operating margins exceeding -320%. The stock's ~$6 billion market cap is a bet on a future that hasn't arrived yet.

Rivals Are Already Circling. Exact Sciences, which Abbott is buying for $21 billion, launched a rival multi-cancer blood test , and Guardant Health's colorectal screening test can also flag multiple tumor types. GRAIL has a head start — its study showed the test increased cancer detection 6.5-fold when added to standard screenings — but first-mover status evaporates quickly if competitors secure approvals and insurance deals of their own.